Low-dose oral or non-oral hormone therapy: Effects on C-reactive protein and atrial natriuretic peptide in menopause

Climacteric

Volumn 18, Issue 1, 2015, Pages 86-93

  Casanova, G ^a   Dos Reis, A M ^b   Spritzer, P M ^c  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Atrial natriuretic peptide; C reactive protein; Cardiovascular risk; Hormone therapy; Menopause; Randomized clinical trial

Indexed keywords

ATRIAL NATRIURETIC FACTOR; C REACTIVE PROTEIN; DROSPIRENONE PLUS ESTRADIOL; ESTRADIOL; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROGESTERONE; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR; ANDROSTANE DERIVATIVE; DRUG COMBINATION; GEL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; HORMONAL THERAPY; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LOW DRUG DOSE; MENSTRUAL CYCLE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; CARDIOVASCULAR DISEASE; DRUG COMBINATION; DRUG EFFECTS; ESTROGEN THERAPY; GEL; INTRADERMAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROCEDURES; RISK FACTOR;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANDROSTENES; ATRIAL NATRIURETIC FACTOR; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DRUG COMBINATIONS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GELS; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS;

EID: 84921264321     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2014.940309     Document Type: Article

References (53)

1. Sternfeld B, Wang H, Quesenberry CP, et al. Physical activity and changes in weight and waist circumference in midlife women: findings from the Study of Women's Health Across the Nation. Am J Epidemiol 2004;160:912-22
2. Cioffi M, Esposito K, Vietri MT, et al. Cytokine pattern in postmenopause. Maturitas 2002;41:187-92
3. El Khoudary SR, Wildman RP, Matthews K, Thurston RC, Bromberger JT, Sutton-Tyrrell K. Endogenous sex hormones impact the progression of subclinical atherosclerosis in women during the menopausal transition. Atherosclerosis 2012;225:180-6
4. Derby CA, Crawford SL, Pasternak RC, Sowers M, Sternfeld B, Matthews KA. Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation. Am J Epidemiol 2009;169:1352-61
5. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002;53:605-19
6. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915
7. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999;100:717-22
8. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538-54
9. Rossouw JE, Cushman M, Greenland P, et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative trials of hormone therapy. Arch Intern Med 2008;168:2245-53
10. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
11. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519
12. Khalil RA. Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease. Biochem Pharmacol 2013;86:1627-42
13. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001;76:13-24
14. Stevenson JC, Durand G, Kahler E, Pertinsky T. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas 2010;67:227-32
15. Hodis HN, Mack WJ. Hormone replacement therapy and the association with coronary heart disease and overall mortality: Clinical application of the timing hypothesis. J Steroid Biochem Mol Biol 2014;142:68-75
16. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409
17. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363-6
18. Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791-804
19. Wild RA, Wu C, Curb JD, et al. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause 2013;20:254-60
20. Bray PF, Larson JC, Lacroix AZ, et al. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol 2008;101:1599-605
21. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40
22. Portaluppi F, Bagni B, Cavallini AR, et al. Plasma levels of atrial natriuretic peptide are increased in normotensive postmenopausal women as a function of age. Cardiology 1991;78:317-22
23. Sala C, Campise M, Ambroso G, Motta T, Zanchetti A, Morganti A. Atrial natriuretic peptide and hemodynamic changes during normal human pregnancy. Hypertension 1995;25:631-6
24. Davidson BJ, Rea CD, Valenzuela GJ. Atrial natriuretic peptide, plasma renin activity, and aldosterone in women on estrogen therapy and with premenstrual syndrome. Fertil Steril 1988;50:743-6
25. Casanova G, Radavelli S, Lhullier F, Spritzer PM. Effects of nonoral estradiol-micronized progesterone or low-dose oral estradiol-drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopause. Fertil Steril 2009;92:605-12
26. Casanova G, Spritzer PM. Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial. Lipids Health Dis 2012;11:133
27. Kupperman HS, Blatt MH, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab 1953;13:688-703
28. Gutkowska J, Genest J, Thibault G, et al. Circulating forms and radioimmunoassay of atrial natriuretic factor. Endocrinol Metab Clin North Am 1987;16:183-98
29. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57
30. Shifren JL, Rifai N, Desindes S, McIlwain M, Doros G, Mazer NA. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin Endocrinol Metab 2008;93:1702-10
31. Van Baal WM, Kenemans P, Emeis JJ, et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil Steril 1999;71:663-70
32. Gurney EP, Nachtigall MJ, Nachtigall LE, Naftolin F. The Women's Health Initiative trial and related studies: 10 years later: A clinician's view. J Steroid Biochem Mol Biol 2014;142:4-11
33. Clarkson TB, Melendez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause 2013;20:342-53
34. Novella S, Heras M, Hermenegildo C, Dantas AP. Effects of estrogen on vascular inflammation: a matter of timing. Arterioscler Thromb Vasc Biol 2012;32:2035-42
35. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010;30:1282-92
36. Donato GB, Fuchs SC, Oppermann K, Bastos C, Spritzer PM. Association between menopause status and central adiposity measured at different cutoffs of waist circumference and waistto-hip ratio. Menopause 2006;13:280-5
37. Davis SR, Castelo-Branco C, Chedraui P, et al. Understanding weight gain at menopause. Climacteric 2012;15:419-29
38. Spritzer PM, Oppermann K. Weight gain and abdominal obesity at menopause. Climacteric 2013;16:292
39. Gambacciani M, Rosano G, Cappagli B, Pepe A, Vitale C, Genazzani AR. Clinical and metabolic effects of drospirenone-estradiol in menopausal woman: a prospective study. Climacteric 2011;14:18-24
40. Odabasi AR, Yuksel H, Karul A, Kozaci D, Sezer SD, Onur E. Effects of standard and low dose 17beta-estradiol plus norethisterone acetate on body composition and leptin in postmenopausal women at risk of body mass index and waist girth related cardiovascular and metabolic disease. Saudi Med J 2007;28:855-61
41. Davidson MH, Maki KC, Marx P, et al. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 2000;160:3315-25
42. de Kraker AT, Kenemans P, Smolders RG, Kroeks MV, van der Mooren MJ. The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a). Maturitas 2004;49:253-63
43. Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012;367:1310-20
44. Hemelaar M, van der Mooren MJ, van Baal WM, Schalkwijk CG, Kenemans P, Stehouwer CD. Effects of transdermal and oral postmenopausal hormone therapy on vascular function: a randomized, placebo-controlled study in healthy postmenopausal women. Menopause 2005;12:526-35
45. Rabbani LE, Seminario NA, Sciacca RR, Chen HJ, Giardina EG. Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women. J Am Coll Cardiol 2002;40:1991-9
46. Danesh J, Saracci R, Berglund G, et al. EPIC-Heart: the cardiovascular component of a prospective study of nutritional, lifestyle and biological factors in 520,000 middle-aged participants from 10 European countries. Eur J Epidemiol 2007;22:129-41
47. Kwok S, Selby PL, McElduff P, et al. Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy. Clin Endocrinol 2004;61:760-7
48. Reuben DB, Palla SL, Hu P, et al. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. Am J Med 2006;119:161-8
49. Maffei S, Del Ry S, Prontera C, Clerico A. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. Clin Sci (Lond) 2001;101:447-53
50. Karjalainen AH, Ruskoaho H, Vuolteenaho O, et al. Effects of estrogen replacement therapy on natriuretic peptides and blood pressure. Maturitas 2004;47:201-8
51. Spinetti A, Margutti A, Bertolini S, et al. Hormonal replacement therapy affects calcitonin gene-related peptide and atrial natriuretic peptide secretion in postmenopausal women. Eur J Endocrinol 1997;137:664-9
52. Belo NO, Sairam MR, Dos Reis AM. Impairment of the natriuretic peptide system in follitropin receptor knockout mice and reversal by estradiol: implications for obesity-associated hypertension in menopause. Endocrinology 2008;149:1399-406
53. Richards AM, Crozier IG. Physiological role of atrial natriuretic peptide. Int J Cardiol 1989;25:141-3